Smith & Nephew’s (SN) “Hold” Rating Reaffirmed at Berenberg Bank

Smith & Nephew (LON:SN)‘s stock had its “hold” rating reaffirmed by stock analysts at Berenberg Bank in a report issued on Friday,Digital Look reports. They presently have a GBX 1,300 price objective on the stock. Berenberg Bank’s price target would suggest a potential upside of 5.22% from the company’s current price.

SN has been the topic of a number of other reports. JPMorgan Chase & Co. restated an “overweight” rating on shares of Smith & Nephew in a report on Friday, November 7th. Royal Bank Of Canada cut Smith & Nephew to a “sector perform” rating and reduced their price objective for the stock from GBX 1,700 to GBX 1,350 in a research note on Wednesday, December 17th. Citigroup raised their price objective on Smith & Nephew from GBX 1,450 to GBX 1,600 and gave the company a “buy” rating in a research note on Friday, October 31st. Finally, Panmure Gordon reiterated a “hold” rating and issued a GBX 1,200 target price on shares of Smith & Nephew in a report on Tuesday, December 9th. Two investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of GBX 1,381.33.

Smith & Nephew Stock Performance

SN stock opened at GBX 1,235.50 on Friday. The firm has a fifty day simple moving average of GBX 1,235.58 and a two-hundred day simple moving average of GBX 1,282.27. The stock has a market capitalization of £13.54 billion, a price-to-earnings ratio of 44.48, a PEG ratio of 0.46 and a beta of 0.62. The company has a debt-to-equity ratio of 70.22, a quick ratio of 0.84 and a current ratio of 2.51.

Insider Buying and Selling at Smith & Nephew

In related news, insider Deepak Nath sold 1,240 shares of Smith & Nephew stock in a transaction dated Tuesday, November 11th. The shares were sold at an average price of GBX 1,257, for a total transaction of £15,586.80. Company insiders own 0.19% of the company’s stock.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.